Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 30-05-2022 | Prostate Cancer | Original Article

Preclinical investigations using [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer

Authors: Viviane J. Tschan, Francesca Borgna, Sarah D. Busslinger, Martina Stirn, Josep M. Monné Rodriguez, Peter Bernhardt, Roger Schibli, Cristina Müller

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2022

Abstract

[¹⁷⁷Lu]Lu-Ibu-DAB-PSMA was previously characterized with moderate albumin-binding properties enabling high tumor accumulation but reasonably low retention in the blood. The aim of this study was to investigate [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA in preclinical in vivo experiments and compare its therapeutic efficacy and potential undesired side effects with those of [¹⁷⁷Lu]Lu-PSMA-617 and the previously developed [¹⁷⁷Lu]Lu-PSMA-ALB-56. BALB/c nude mice without tumors were investigated on Day 10 and 28 after injection of 10 MBq radioligand. It was revealed that most plasma parameters were in the same range for all groups of mice and histopathological examinations of healthy tissue did not show any alternations in treated mice as compared to untreated controls. Based on these results, a therapy study over twelve weeks was conducted with PC-3 PIP tumor-bearing mice for comparison of the radioligands’s therapeutic efficacy up to an activity of 10 MBq (1 nmol) per mouse. In agreement with the increased mean absorbed tumor dose, [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA (~ 6.6 Gy/MBq) was more effective to inhibit tumor growth than [¹⁷⁷Lu]Lu-PSMA-617 (~ 4.5 Gy/MBq) and only moderately less potent than [¹⁷⁷Lu]Lu-PSMA-ALB-56 (~ 8.1 Gy/MBq). As a result, the survival of mice treated with 2 MBq of an albumin-binding radioligand was significantly increased (p < 0.05) compared to that of mice injected with [¹⁷⁷Lu]Lu-PSMA-617 or untreated controls. The majority of mice treated with 5 MBq or 10 MBq [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA or [¹⁷⁷Lu]Lu-PSMA-ALB-56 were still alive at study end. Hemograms of immunocompetent mice injected with 30 MBq [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA or 30 MBq [¹⁷⁷Lu]Lu-PSMA-617 showed values in the same range as untreated controls. This was, however, not the case for mice treated with [¹⁷⁷Lu]Lu-PSMA-ALB-56 which revealed a drop in lymphocytes and hemoglobin at Day 10 and Day 28 after injection. The data of this study demonstrated a significant therapeutic advantage of [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA over [¹⁷⁷Lu]Lu-PSMA-617 and a more favorable safety profile as compared to that of [¹⁷⁷Lu]Lu-PSMA-ALB-56. Based on these results, [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA may has the potential for a clinical translation.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, et al. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987–8. https://doi.org/10.1007/s00259-014-2978-1.CrossRefPubMed

Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57:97S-104S. https://doi.org/10.2967/jnumed.115.170167.CrossRefPubMed

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating ¹⁷⁷Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90. https://doi.org/10.2967/jnumed.116.183194.CrossRefPubMed

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center Phase II prospective trial of ¹⁷⁷Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857–65. https://doi.org/10.2967/jnumed.119.236414.CrossRefPubMedPubMedCentral

Rahbar K, Bodei L, Morris MJ. Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the Phase III VISION trial and its importance for the future of theranostics. J Nucl Med. 2019;60:1504–6. https://doi.org/10.2967/jnumed.119.234054.CrossRefPubMed

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107322.CrossRefPubMedPubMedCentral

Dumelin CE, Trüssel S, Buller F, Trachsel E, Bootz F, Zhang Y, et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl. 2008;47:3196–201. https://doi.org/10.1002/anie.200704936.CrossRefPubMed

10.

Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, et al. ¹⁷⁷Lu-Labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics. 2017;7:1928–39. https://doi.org/10.7150/thno.18719.CrossRefPubMedPubMedCentral

11.

Benesova M, Umbricht CA, Schibli R, Müller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934–46. https://doi.org/10.1021/acs.molpharmaceut.7b00877.CrossRefPubMed

12.

Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4004-5.CrossRefPubMed

13.

Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wustemann T, Barelli P, Kim D, et al. Double targeting ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.116.188722.CrossRefPubMed

14.

Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, et al. Enhancing treatment efficacy of ¹⁷⁷Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol Pharm. 2018;15:5183–91. https://doi.org/10.1021/acs.molpharmaceut.8b00720.CrossRefPubMed

15.

Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, DiMagno SG, et al. Albumin-binding PSMA ligands: implications for expanding the therapeutic window. J Nucl Med. 2019;60:656–63. https://doi.org/10.2967/jnumed.118.221150.CrossRefPubMed

16.

Umbricht CA, Benesova M, Schibli R, Müller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297–306. https://doi.org/10.1021/acs.molpharmaceut.8b00152.CrossRefPubMed

17.

Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, et al. ¹⁷⁷Lu-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio. J Nucl Med. 2021;62:521–7. https://doi.org/10.2967/jnumed.120.250738.CrossRefPubMedPubMedCentral

18.

Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [¹⁷⁷Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05022-3.CrossRefPubMedPubMedCentral

19.

Deberle LM, Benesova M, Umbricht CA, Borgna F, Büchler M, Zhernosekov K, et al. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10:1678–93. https://doi.org/10.7150/thno.40482.CrossRefPubMedPubMedCentral

20.

Benesova M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20. https://doi.org/10.2967/jnumed.114.147413.CrossRefPubMed

21.

Salvat F. PENELOPE2014: A code system for Monte-Carlo simulation of electron and photon transport. OECD/NEA Data Bank: NEA/NSC/DOC. 2015;3.

22.

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMed

23.

Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate. 2009;69:1128–41. https://doi.org/10.1002/pros.20962.CrossRefPubMedPubMedCentral

24.

Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919–30. https://doi.org/10.1007/s00259-019-04345-0.CrossRefPubMedPubMedCentral

25.

Siwowska K, Guzik P, Domnanich KA, Monne Rodriguez JM, Bernhardt P, Ponsard B, et al. Therapeutic potential of ⁴⁷Sc in comparison to ¹⁷⁷Lu and ⁹⁰Y: preclinical investigations. Pharmaceutics. 2019;11. https://doi.org/10.3390/pharmaceutics11080424.

26.

Binder T, Diem H, Fuchs R, Gutensohn K, Nebe T. Pappenheim stain: description of a hematological standard stain - history, chemistry, procedure, artifacts and problem solutions. J Lab Med. 2012;36:293–309. https://doi.org/10.1515/labmed-2012-0027.CrossRef

27.

Haller S, Reber J, Brandt S, Bernhardt P, Groehn V, Schibli R, et al. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. Nucl Med Biol. 2015;42:770–9. https://doi.org/10.1016/j.nucmedbio.2015.06.006.CrossRefPubMed

28.

Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, et al. Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors. Bioconjug Chem. 2018;29:3213–21. https://doi.org/10.1021/acs.bioconjchem.8b00556.CrossRefPubMed

29.

Ling X, Latoche JD, Choy CJ, Kurland BF, Laymon CM, Wu Y, et al. Preclinical dosimetry, imaging, and targeted radionuclide therapy studies of Lu-177-labeled albumin-binding, PSMA-targeted CTT1403. Mol Imaging Biol. 2020;22:274–84. https://doi.org/10.1007/s11307-019-01404-8.CrossRefPubMedPubMedCentral

30.

Fendler WP, Stuparu AD, Evans-Axelsson S, Luckerath K, Wei L, Kim W, et al. Establishing ¹⁷⁷Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med. 2017;58:1786–92. https://doi.org/10.2967/jnumed.117.193359.CrossRefPubMedPubMedCentral

31.

Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted ¹⁷⁷Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013;54:124–31. https://doi.org/10.2967/jnumed.112.107235.CrossRefPubMed

32.

Benesova M, Guzik P, Deberle LM, Busslinger SD, Landolt T, Schibli R, et al. Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities. Mol Pharm. 2022;19:963–73. https://doi.org/10.1021/acs.molpharmaceut.1c00932.CrossRefPubMed

33.

Iikuni S, Kamei I, Ohara T, Watanabe H, Ono M. Development of an ¹¹¹In-labeled glucagon-like peptide-1 receptor-targeting exendin-4 derivative that exhibits reduced renal uptake. Mol Pharm. 2022;19:1019–27. https://doi.org/10.1021/acs.molpharmaceut.2c00068.CrossRefPubMed

34.

Schneck K, Washington M, Holder D, Lodge K, Motzel S. Hematologic and serum biochemical reference values in nontransgenic FVB mice. Comp Med. 2000;50:32–5.PubMed

35.

Kristiansson A, Vilhelmsson Timmermand O, Altai M, Strand J, Strand S-E, Åkerström B, et al. Hematological toxicity in mice after high activity injections of ¹⁷⁷Lu-PSMA-617. Pharmaceutics. 2022;14:731.CrossRef

36.

Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of ¹⁷⁷Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976–83. https://doi.org/10.1007/s00259-015-3125-3.CrossRefPubMed

37.

Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for ¹⁷⁷Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2017;58:445–50. https://doi.org/10.2967/jnumed.116.178483.CrossRefPubMed

38.

Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol. 2021;79:343–50. https://doi.org/10.1016/j.eururo.2020.11.013.CrossRefPubMed

Title: Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
Authors: Viviane J. Tschan
Francesca Borgna
Sarah D. Busslinger
Martina Stirn
Josep M. Monné Rodriguez
Peter Bernhardt
Roger Schibli
Cristina Müller
Publication date: 30-05-2022
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05837-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Preclinical investigations using [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2022

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T

Total-body pediatric PET is ready for prime time

Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

Imaging PARP with [18F]rucaparib in pancreatic cancer models